Ruti Aga Handed Six-Year Ban After Family Member Forged Her Prescription

Ethiopian marathon runner and 2026 Tokyo Marathon champion Ruti Aga has been banned for six years by the Athletics Integrity Unit (AIU). The sanction is not solely for the presence of a prohibited substance in her sample, but for a forged prescription submitted in her defence—a document prepared by a member of her own family. The ban, effective from 10 September, effectively ends the career of the 32-year-old. The AIU said in a statement issued on Thursday that the sanction is split into two parts: two years for the presence of a prohibited substance, and four years for tampering with the anti-doping process. Six years in total. According to the statement, the prescription was attributed to a clinic that does not exist, and the person who allegedly issued it held no medical registration. The AIU also stressed that misleading information was given during interviews conducted as part of the investigation, strengthening the tampering charge. One technical detail is central to this case and has been widely misreported. The substance found in Aga's sample, methylprednisolone, is a glucocorticoid—WADA Prohibited List class S9—not an anabolic steroid (class S1). The distinction is not merely semantic; it determines the legal direction of the entire case. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only when administered by injection, orally or rectally. The direct consequence is that a therapeutic injection given out of competition is entirely legal. A violation arises only when residues are present in a sample taken in-competition. In road running, the in-competition window generally opens at 23:59 the day before the race, so an injection given days earlier can still be caught. Aga therefore had a legitimate defence pathway available: to properly establish the route of administration, the timing and the medical necessity. She did not take it. According to the sequence of events, Aga was tested after winning a half marathon in China in March, and the sample returned positive. In her defence she cited a knee injury and claimed a doctor had administered a methylprednisolone injection. A prescription was submitted in support. The AIU's verification found the document failed at three independent levels. First, the clinic named on the prescription did not exist. Second, the family member who allegedly issued it held no medical registration. Third, that person claimed to have used an old prescription pad from a former workplace, a claim the clinic in question explicitly disowned. Three independent verifications, three failures. The knee-injury explanation is not inherently implausible. Intra-articular or peri-articular glucocorticoid injection for knee synovitis is standard sports-medicine practice in distance runners, for whom chronic knee pathology is a known consequence of high training and racing loads. That plausibility is precisely why the forgery proved decisive: a genuinely documented treatment would have been defended with real medical records. Fabricating a prescription implies the genuine paperwork did not exist. Aga's competitive record is genuinely elite. She won the 2026 Tokyo Marathon, a World Marathon Major, and has finished second at World Marathon Majors on three occasions. Her personal best is understood to sit in the 2:18 to 2:20 range, although the source material for this report does not state an exact mark. That level of performance places her among the leading women marathoners in the world—a record now read in a different light. The career impact is severe. Aga is 32. By the time a six-year ban expires she will be around 38. Ethiopia's depth in women's marathon is so extreme that a 38-year-old returning athlete with a doping record has essentially no realistic path back into national selection. The 2028 Olympic cycle is closed to her entirely. The ban is technically six years; in practical terms it is a lifetime sanction. It is not stated whether her earlier results have been annulled. Under standard AIU practice, results and prize money from the competition at which the sample was collected—the March half marathon in China—are disqualified. Results before that date, including the 2026 Tokyo title, are not automatically voided absent a finding of earlier use. The statement does not specify the scope of disqualification. The arithmetic of the sanction is itself revealing. Two years corresponds to the standard sanction for presence of a specified substance where intent is not established. Four years is the Code's standard sanction for tampering. Together they make six. This arithmetic indicates that the panel rejected the no-significant-fault mitigation that would ordinarily reduce the presence sanction. In other words, the knee injury and treatment claim did not hold as a defence. Backdating the ban to 10 September is a procedural convenience, not a reduction. Time served under provisional suspension counts against the total, so the athlete gains no real benefit. That date marks the start of the provisional suspension, and the final sanction runs from it. The regulatory framework matters to understanding the outcome. The case was brought under the World Athletics Anti-Doping Rules, enforced by the AIU, applying the 2026 WADA Code and the WADA Prohibited List. Under that framework, glucocorticoids are prohibited only when injected in-competition, whereas anabolic steroids are prohibited at all times. That distinction changes the entire shape of the case. But the more important question is why Aga felt the need to take such a step. The answer lies in the system around her. The statement indicates she had no credentialed team physician. A family member with no medical registration was acting as the treating figure. This is not a filing error; it is the signature of an athlete operating without formal medical support. Nor does there appear to have been any Therapeutic Use Exemption infrastructure. A properly managed athlete would either hold a TUE or apply for one, or would observe the route-specific washout period set out by WADA. Neither appears to have happened. When no valid treatment record existed, one was manufactured. This goes beyond individual negligence. Economic pressure cannot be ignored either. A large share of a marathoner's income comes from appearance fees. For an injured athlete, withdrawing from a race is expensive in both income and visibility. That creates pressure to mask pain and race, and glucocorticoids are the cheapest and most readily available tool for doing so. The forgery is downstream of that untreated governance gap. A further dimension concerns the tightening scrutiny of road races in China. Large appearance-fee budgets, deep East African elite fields and AIU testing presence coincide at these events. That combination has made this tier of racing a focal point for enforcement. The tier where athletes earn most is also the tier where they are tested most aggressively. The ban will have no effect on the competitive structure of Ethiopian women's marathon. The country has an entire generation of world-record-class runners. The removal of a 32-year-old with no global championship medals does not alter national selection calculus in any measurable way. The real issue is not the sport but governance. An appeal remains theoretically open. There is typically a window of around 21 days from receipt of the reasoned decision to lodge an appeal with the Court of Arbitration for Sport. In this case the prospects are slim, because the tampering finding rests on documents that have been shown to be false. The decision will remain contested. On one side it will be cited as evidence of AIU rigour, given that a six-year ban was imposed for a substance with no proven endurance benefit. On the other it will be cited as evidence of disproportionate enforcement against African road runners. Both arguments have their adherents. What is clear is this: had Aga kept a genuine record of her knee treatment and followed the correct process at the correct time, the case might never have existed. The six-year ban was delivered not by the substance, but by the forged paper.